Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
8.40
+0.30 (3.70%)
At close: Mar 9, 2026, 4:00 PM EDT
8.41
+0.01 (0.12%)
After-hours: Mar 9, 2026, 5:35 PM EDT

Kyverna Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2022
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21
478162---
Market Cap Growth
290.24%----
Enterprise Value
313.77-120.05000
Last Close Price
8.403.74---
PE Ratio
--1.12---
PB Ratio
2.420.61---
P/TBV Ratio
2.390.54---
P/FCF Ratio
--1.39---
P/OCF Ratio
--1.41---
EV/EBITDA Ratio
-0.85---
EV/EBIT Ratio
-0.84---
EV/FCF Ratio
-1.03---
Debt / Equity Ratio
0.010.020.130.180.08
Debt / EBITDA Ratio
-0.03-0.06-0.15-0.37-0.22
Debt / FCF Ratio
-0.03-0.07-0.17-0.29-0.24
Net Debt / Equity Ratio
-1.09-1.040.370.551.52
Net Debt / EBITDA Ratio
0.981.980.801.442.74
Net Debt / FCF Ratio
1.052.380.911.113.01
Asset Turnover
-000.090.07
Quick Ratio
5.058.472.904.294.78
Current Ratio
5.168.613.054.454.84
Return on Equity (ROE)
-76.93%-80.74%-125.95%-52.95%-42.18%
Return on Assets (ROA)
-69.78%-75.09%-87.82%-38.56%-30.82%
Return on Invested Capital (ROIC)
1355.45%2732.66%-1880.27%-943.00%-8581.76%
Return on Capital Employed (ROCE)
-80.90%-87.43%-113.15%-47.19%-37.88%
Earnings Yield
-33.55%-89.04%---
FCF Yield
-32.88%-72.05%---
Buyback Yield / Dilution
-0.62%-211.25%---
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q